Illumina shares may be trading near fair value following an upward revision to earnings forecasts. Based on recent free cash flow and DCF estimates, the outlook for future growth is viewed as consistent with the share price.
Illumina shares are trading at around $273.90, broadly in line with the valuation indicated by the DCF analysis. The market appears to be incorporating the strength of cash flow and the outlook for future growth into its valuation.
Free cash flow over the trailing 12 months was approximately $942.9 million. The model projects that it will exceed $1 billion over the next few years and continue growing over the 10-year period.
The company reported 9.5% year-on-year revenue growth and solid demand for sequencing platforms and clinical consumables in the second quarter of 2026, leading to the view that improving financial conditions are influencing the share price.
Commentary also points to the company’s narrative analysis and insider trading, suggesting that the share price valuation depends on multiple factors.